BCAX
Income statement / Annual
Last year (2024), Bicara Therapeutics Inc. Common Stock's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Bicara Therapeutics Inc. Common Stock's net income was -$68.00 M.
See Bicara Therapeutics Inc. Common Stock,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$56.00 K
|
$19.00 K
|
$10.00 K
|
| Gross Profit |
-$56.00 K
|
-$19.00 K
|
-$10.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
| Research and Development Expenses |
$8.22 M
|
$30.62 M
|
$31.31 M
|
| General & Administrative Expenses |
$18.77 M
|
$9.27 M
|
$6.34 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$18.77 M
|
$9.27 M
|
$6.34 M
|
| Other Expenses |
$55.40 M
|
$0.00
|
$0.00
|
| Operating Expenses |
$82.39 M
|
$39.89 M
|
$37.66 M
|
| Cost And Expenses |
$82.39 M
|
$39.89 M
|
$37.66 M
|
| Interest Income |
$14.58 M
|
$1.31 M
|
$4.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$112.00 K
|
| Depreciation & Amortization |
$56.00 K
|
$19.00 K
|
$10.00 K
|
| EBITDA |
-$67.75 M |
-$51.96 M |
-$37.72 M |
| EBITDA Ratio |
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$14.58 M
|
-$12.09 M
|
-$188.00 K
|
| Income Before Tax |
-$67.81 M
|
-$51.98 M
|
-$37.84 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
| Income Tax Expense |
$187.00 K
|
$5.00 K
|
$1.00 K
|
| Net Income |
-$68.00 M
|
-$51.99 M
|
-$37.85 M
|
| Net Income Ratio |
0
|
0
|
0
|
| EPS |
-1.25 |
-1 |
-0.73 |
| EPS Diluted |
-1.25 |
-1 |
-0.73 |
| Weighted Average Shares Out |
$54.42 M
|
$51.76 M
|
$51.76 M
|
| Weighted Average Shares Out Diluted |
$54.42 M
|
$51.76 M
|
$51.76 M
|
| Link |
|
|
|
